6-[(4-chlorophenyl)methyl]-N-(2-methoxyethyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 英文名称: 6-[(4-chlorophenyl)methyl]-N-(2-methoxyethyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide
• 化学式: C₁₉H₂₁ClN₄O₂
• mdl: MFCD15097268
• 分子量: 372.8
• InChiKey: BUDLURQSYSCYGM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  68.5
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• New compounds
  申请人：Lundback Thomas

  公开号：US20080221129A1

  公开（公告）日：2008-09-11

  The present invention relates to compounds of the formula (I): including pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers, and N-oxides thereof, said compounds being useful as inhibitors of stearoyl-CoA desaturase (SCD). The invention further relates to the use of compounds of the formula (I) for treatment of medical conditions in which the modulation of SCD activity is beneficial, such as cardiovascular diseases, obesity, non-insulin-dependent diabetes mellitus, hypertension, neurological diseases, immune disorders, cancer, essential fatty acid deficiency, acne, psoriasis, rosacea or other skin conditions.

  本发明涉及式（I）化合物，包括其药学上可接受的盐、溶剂合物、水合物、几何异构体、互变异构体、光学异构体和N-氧化物，该化合物可用作硬脂酰辅酶A脱饱和酶（SCD）的抑制剂。本发明还涉及使用式（I）化合物治疗调节SCD活性有益的医疗情况，如心血管疾病、肥胖症、非胰岛素依赖性糖尿病、高血压、神经疾病、免疫紊乱、癌症、必需脂肪酸缺乏症、痤疮、银屑病、酒渣鼻或其他皮肤病。
• [EN] PYRAZOLO [1,5-A] PYRIMIDINE ANALOGS FOR USE AS INHIBITORS OF STEAROYL-COA DESATURASE (SCD) ACTIVITY<br/>[FR] ANALOGUES DE PYRAZOLO [1,5-A] PYRIMIDINE UTILISABLES COMME INHIBITEURS DE L'ACTIVITÉ STÉAROYL-COA DÉSATURASE (SCD)
  申请人：BIOVITRUM AB PUBL

  公开号：WO2008003753A1

  公开（公告）日：2008-01-10

  [EN] The present invention relates to compounds of the formula (I): including pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers, and N-oxides thereof, said compounds being useful as inhibitors of stearoyl-CoA desaturase (SCD). The invention further relates to the use of compounds of the formula (I) for treatment of medical conditions in which the modulation of SCD activity is beneficial, such as cardiovascular diseases, obesity, non- insulin-dependent diabetes mellitus, hypertension, neurological diseases, immune disorders, cancer, essential fatty acid deficiency, acne, psoriasis, rosacea or other skin conditions.
  [FR] La présente invention concerne des composés de formule (I) et des sels, solvates, hydrates, isomères géométriques, tautomères, isomères optiques et N-oxydes pharmaceutiquement acceptables de ces composés, lesdits composés s'avérant utiles en tant qu'inhibiteurs de la stéaroyl-CoA désaturase (SCD). L'invention concerne également l'utilisation de composés de formule (I) dans le cadre du traitement de troubles contre lesquels la modulation de l'activité de la SCD s'avère bénéfique, notamment les maladies cardiovasculaires, l'obésité, le diabète sucré non insulino-dépendant, l'hypertension, les maladies neurologiques, les troubles immunitaires, le cancer, le manque d'acides gras essentiels, l'acné, le psoriasis, la couperose ou d'autres troubles cutanés.